Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics Chief Financial Officer Patrick Fabbio reported new equity awards in the company. On January 16, 2026, he received 28,000 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second and third anniversaries of January 16, 2026, as long as he remains in continuous service. After this grant, he directly beneficially owned 70,439 shares of common stock.
On the same date, he was also granted 175,000 stock options with an exercise price of $5.01 per share. For these options, 25% vest on the one-year anniversary of January 16, 2026, and the remaining portion vests in equal monthly installments over the following three years, also conditioned on continued service. Following this grant, he directly held 175,000 stock options in total.
Protara Therapeutics VP and Controller Hannah Fry reported new equity awards. On January 16, 2026, she received 9,500 shares of common stock at a price of $0, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, contingent on her continued service.
Fry was also granted a stock option for 55,000 shares of common stock with an exercise price of $5.01 per share, expiring on January 15, 2036. According to the award terms, 25% of these option shares vest on the one-year anniversary of January 16, 2026, and the remainder vest in equal monthly installments over the following three years, subject to continued service. After the RSU grant, she beneficially owned 46,312 common shares directly, and 55,000 options.
Protara Therapeutics, Inc. reported an equity compensation grant to its Chief Medical Officer, Nicacio Leonardo Viana. On January 16, 2026, he received stock options for 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. These options vest with 25% of the shares on the one-year anniversary of January 16, 2026, and the remaining shares vest in monthly installments over the following three years, conditioned on continued service.
He also acquired 26,000 shares of common stock at a price of $0 pursuant to restricted stock unit awards. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, also subject to continued service. Following these awards, he beneficially owns 78,181 shares of common stock directly, in addition to the unexercised options.
Protara Therapeutics CEO and President Jesse Shefferman reported new equity awards. On January 16, 2026, he received 87,000 shares of common stock at a price of $0 pursuant to restricted stock unit (RSU) awards, bringing his directly held common shares to 1,046,886.
He was also granted stock options covering 524,000 shares of common stock at an exercise price of $5.01 per share, with 524,000 derivative securities held directly after the grant. The RSUs vest in three equal annual installments on the first, second, and third anniversaries of January 16, 2026, contingent on his continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in equal monthly installments over the next three years, also subject to continued service, and expire on January 15, 2036.
Protara Therapeutics reported an equity compensation grant to its Chief Scientific Operations Officer, Jacqueline Zummo. On January 16, 2026, she received 30,000 shares of common stock for $0, issued pursuant to restricted stock unit awards. Following this grant, she beneficially owned 128,861 common shares directly.
The filing also shows a grant of 180,000 stock options with a $5.01 exercise price, recorded at a $0 acquisition cost. The RSUs vest in three equal annual installments on the first, second and third anniversaries of January 16, 2026, contingent on continued service. The options vest 25% on the one-year anniversary of January 16, 2026, with the remaining 75% vesting in 1/48th monthly installments over the next three years, also conditioned on ongoing service.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 2,408,868 shares of Protara Therapeutics, Inc. common stock, representing 4.7% of the outstanding class as of 12/31/2025. BlackRock reports sole power to vote 2,380,664 of these shares and sole power to dispose of 2,408,868 shares, with no shared voting or dispositive power.
The holdings reflect securities owned or deemed owned by certain BlackRock business units, excluding other disaggregated units. The shares are held in the ordinary course of business, and BlackRock states they were not acquired to change or influence control of Protara. Various underlying persons have rights to dividends or sale proceeds, but no one person has more than 5% of Protara’s total outstanding common shares.
Protara Therapeutics, Inc. reports that underwriters have fully exercised their option to purchase an additional 1,956,521 shares of its common stock at the public offering price of $5.75 per share, following a previously completed sale of 13,043,479 shares. Including this option exercise, the public offering is expected to generate aggregate gross proceeds of approximately $86.3 million before underwriting fees and other expenses.
The company plans to use the net proceeds primarily to fund the clinical development of TARA-002 and other clinical programs, and may also allocate funds to working capital and general corporate purposes. The shares were issued under an effective shelf registration statement on Form S-3 and a related prospectus supplement.
Protara Therapeutics, Inc. entered into an underwriting agreement to sell 13,043,479 shares of its common stock at $5.75 per share, for expected gross proceeds of approximately $75 million. The offering, made under an effective shelf registration on Form S-3, closed on December 8, 2025.
The company granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares at the public offering price, less underwriting discounts and commissions. Protara plans to use the net proceeds primarily to fund clinical development of its lead candidate TARA-002 and other clinical programs, and may also apply funds to working capital and other general corporate purposes. The company and its officers and directors agreed to 60-day lock-up provisions that temporarily restrict additional share sales.
Protara Therapeutics reported updated interim Phase 2 data for TARA-002 in patients with carcinoma in situ non-muscle invasive bladder cancer who had not received BCG. Among 29 evaluable BCG-Naïve patients as of November 7, 2025, the complete response rate was 72% at any time, 69% at six months (18/26), and 50% at 12 months (7/14). Initial responders showed durable outcomes, with 88% maintaining response through six months and all three patients evaluated at 12 months remaining in response. Re-induction converted most initial non-responders, and all re-induced responders maintained responses at 12 months. Safety appeared manageable, with most treatment-related side effects mild and no Grade 3 or higher events or discontinuations. The FDA has provided written feedback supporting a registrational controlled trial design in BCG-Naïve patients using intravesical chemotherapy as the comparator and a six-month complete response rate as the primary endpoint.
Protara Therapeutics reported interim clinical results from its ongoing Phase 2 STARBORN-1 trial of TARA-002, an investigational cell-based therapy for pediatric patients with lymphatic malformations (LMs). The analysis covers 12 enrolled patients who received more than one dose as of the November 12, 2025 cutoff. Eight patients were evaluable at eight weeks and seven of these eight achieved clinical success, meaning at least a 60% reduction in LM volume by imaging or investigator assessment. Overall, 8 of 10 patients who completed treatment and all 8 patients who completed the eight-week response assessment achieved clinical success.
Among macrocystic patients, 5 of 6 achieved a complete response and the remaining patient had a substantial response; the only mixed-cystic patient achieved a complete response. Two patients reached a 32-week post-treatment assessment and remained disease-free, while one initial complete response was later reclassified as a ranula. Most adverse events were mild to moderate, with no serious events reported; the most common were swelling and fatigue, and one patient discontinued due to Grade 2 fatigue. Protara also posted an investor presentation and press release, and held a conference call and webcast to discuss the data.